There’s a new clinical trial about to get started in SF looking for 25 men or transwomen who are at relatively low risk for HIV to test the safety, tolerability and acceptability of a very long acting (injected once every three months) for Pre-exposure prophylaxis (PrEP). If that sounds like you or someone you know, …
Injection Every 3 Months to Prevent HIV- Study in San Francisco Enrolling Now Read More »
Healthcare providers should advise people at “substantial risk” for HIV infection about pre-exposure prophylaxis (PrEP) using tenofovir/emtricitabine, or Truvada, according to new guidelines issued by the U.S. Centers for Disease Control and Prevention (CDC). This includes HIV negative people in an ongoing sexual relationship with HIV positive partners, gay or bisexual men who have had sex …
New CDC Guidelines: People at Risk for HIV Should Consider Truvada PrEP Read More »
GSK744, an investigational integrase inhibitor, and TMC278 LA (a long-acting, injectable form of the NNRTI rilpivirine [Edurant]) both showed safety and efficacy when administered in once-monthly or once-quarterly doses, according to a study presented at IAS 2013. There were no drug-related serious adverse events and all adverse events were either mild or moderate. The phase 1 …
Reality Check: Is the End of AIDS in Sight? Dr Francois Dabis from the Bordeaux School of Public Health at the University of Bordeaux (Segalen, France) gave an excellent talk today at CROI-2013 that is easily understood by any lay person who wants to know how far we have come in HIV and the challenges ahead …
Mark Mascolini (natap.org) An FDA advisory panel left little doubt that Truvada, the once-daily pill combining tenofovir and emtricitabine, will get its license extended to cover pre-exposure prophylaxis (PrEP) of HIV infection in adults with a high risk of picking up HIV sexually. But the thorny deliberations leading to that endorsement in a marathon 12.5-hour …
FDA Advisors Endorse Truvada to Prevent HIV Infection–But Big Questions Remain Read More »
